Biotechnology
Commented by Fabian Lorenz on February 13th, 2025 | 07:10 CET
ACQUISITION?! Renk, BioNTech, and Biotech Highflyer Vidac Pharma
Is Renk about to be taken over? Quite possible. The Company, known for its transmissions for the Leopard tank, has a new major shareholder. And it turns out to be none other than KNDS – the maker of the Leopard 2 tank. The Renk share price reacted with a jump of 10%. Is there more to come? Vidac Pharma is also frequently mentioned as a potential takeover candidate. Like BMW, the Company is working on a "new class". But in this case, it is to save human lives. To this end, last year's biotech highflyer aims to revolutionize cancer treatment. Experts believe that a multiplication of the share price is possible. BioNTech is also fighting cancer. In addition to its own research, the German company is strategically focusing on acquisitions. Another one has just been completed. What is next?
Read
Commented by Fabian Lorenz on February 10th, 2025 | 07:30 CET
BIOTECH stocks in RALLY MODE: Valneva, BioNxt Solutions, Evotec – BUY signal or correction?
After the 50% rally, the stock of BioNxt Solutions is currently consolidating. However, the next buy signal could be generated soon. There will likely be some exciting announcements this year and perhaps even a strategic partnership. The new R&D site in Munich will likely also attract attention for the innovative biotech company in Germany. After the catastrophic year, things have quieted down for the time being at Evotec. Or is it more that the air has been let out? After all, there is a lot of uncertainty about what skeletons might still be in the closet and how things should continue strategically. The stock market does not like that. In contrast, Valneva has had an impressive rally since mid-January. Last week, there was another big announcement. After 50%, is there more potential with the French company?
Read
Commented by Fabian Lorenz on February 4th, 2025 | 07:30 CET
OPPORTUNITIES in the Tariff Crash: TUI Facing a 50% Price Surge? Valneva Stock Strong! Multiplier with Desert Gold?
CAD 10 per ounce of gold. This is the current valuation of Desert Gold's resource - a real bargain with a gold price of over USD 2,800. There are good reasons why Desert Gold's share price should rise soon. Analysts even consider a multiplication of its value to be possible. Last week, Valneva showed just how quickly a stock can suddenly jump by 20% or more. Thanks to a multi-million dollar order from the US military, the downward trend in the share price has been broken. Are further price gains possible? Experts at TUI believe a 50% price jump is achievable. But is optimism ahead? Do these stocks offer opportunities in the tariff crash?
Read
Commented by Juliane Zielonka on January 31st, 2025 | 06:55 CET
Vidac Pharma, Bayer AG, Novo Nordisk: Three companies that will shape the pharmaceutical landscape in 2025
The pharmaceutical industry is again demonstrating its market power between innovation and risk: Vidac Pharma reports a milestone in colorectal cancer therapy with VDA1275. The combination of the active ingredient with a chemotherapeutic agent achieves a 38.9% tumor reduction in preclinical studies. This synergy effect raises hope for gentler chemotherapy treatments and more innovative approaches. Bayer AG is making waves at the JP Morgan Health Conference with its pharmaceutical pipeline: the prostate cancer drug Nubeqa™ achieves blockbuster status with revenue of EUR 1 billion. In women's health, the first non-hormonal therapy for menopausal symptoms is expected to reach the US market as early as 2025. Novo Nordisk, on the other hand, is threatened with a class-action lawsuit in the billion-dollar market for obesity drugs: the REDEFINE-1 study on the promising drug CagriSema revealed weaknesses in the study design. After the results were made public, the share price fell by 18%. While Vidac Pharma and Bayer impress with precise study results, the Novo Nordisk case shows the fragility of methodological fuzziness. The details.
Read
Commented by André Will-Laudien on January 27th, 2025 | 07:40 CET
Biotech - Here we go! 100% opportunities for Evotec, BioNxt, Bayer, Formycon, and Novo Nordisk!
Last week, the DAX 40 index reached a new all-time high of 21,520 points. At first glance, this sounds odd because half of the stocks are languishing at multi-year lows. However, the driving forces are the heavyweights SAP, Siemens, Allianz, Airbus, and Deutsche Telekom. They are pushing the index upward daily, putting ETF fund managers under pressure as they have to adjust the weightings accordingly. However, the more capital flows into the leading stocks, the more investors are looking for lagging stocks that could successfully turn the chart around due to operational turning points. We select a few opportunity stocks.
Read
Commented by Armin Schulz on January 22nd, 2025 | 07:00 CET
Evotec, Vidac Pharma, BioNTech – Profiting from the fight against cancer
It has been clear for some time that cancer can affect anyone, and not just since King Charles and Princess Kate made their battles with cancer public. The market is growing, and today, revenues in this area are already in the billions. This is driven by an aging population and increasingly unhealthy lifestyles. The margins for manufacturers of cancer drugs are often in the high double-digit percentage range. It is no wonder that companies are focusing on the fight against cancer. Developing a medication that reliably defeats the disease could result in a genuine blockbuster. In 2023, around USD 223 billion was spent on cancer drugs worldwide. We are looking at three companies striving to cure cancer and claim their share of this lucrative market.
Read
Commented by Armin Schulz on January 21st, 2025 | 07:30 CET
Bayer awakened! BioNxt Solutions, Novo Nordisk – Invest in tomorrow's winners today
The economy is at a turning point, as the rapid advancements in artificial intelligence are enabling technological innovations that set new benchmarks. Revolutionary developments are emerging, particularly in the pharmaceutical industry, medical technology, and biotechnology. These sectors not only unlock groundbreaking medical possibilities but also offer significant economic growth potential. Investors who move in early to disruptive technologies or dynamic growth industries can count on attractive returns. But which players are dominating this wave of innovation? And how can you, as an investor, benefit strategically? A closer look is worthwhile.
Read
Commented by Stefan Feulner on January 14th, 2025 | 07:55 CET
Qiagen, Vidac Pharma, and Bayer with groundbreaking news
In the years to come, biotechnology will play a central role in solving global challenges. From the development of innovative therapies to sustainable agriculture and biobased industries, biotechnology combines science and technology to make the world more sustainable and efficient. As a driver of growth and innovation, it offers enormous opportunities for companies and investors who want to actively shape the future.
Read
Commented by André Will-Laudien on January 6th, 2025 | 07:00 CET
Biotech-Rally 2025: Evotec, BioNTech, Vidac Pharma, Pfizer and Bayer are on the buy list
For two years, there was almost no movement in the biotech sector. Not even the trend of falling interest rates that began in 2024 could persuade investors to make larger investments. Meanwhile, AI and high-tech stocks continued to perform well, driving the Nasdaq 100 index up by over 30%. However, in the last quarter of 2024, some bombed-out life sciences stocks saw significant markups, and new takeover rumours also began circulating. Whether the sentiment can continue to rise in the coming weeks is something we will explore further. Let's take a closer look at our top picks for 2025.
Read
Commented by Armin Schulz on December 27th, 2024 | 07:10 CET
Volkswagen, Globex Mining, Novo Nordisk – Here are the opportunities for the coming year
The vbw commodity price index recorded a remarkable increase of 4.4% in October 2024 compared to the previous month – an increase of 18.4% year-on-year. On the one hand, this is surprising, as the economy has reportedly noticeably slowed down. On the other hand, geopolitical tensions seem to be causing overcompensation. Raw materials are the engine of the economy, and it is not for nothing that the price of copper is considered a leading indicator of economic activity. In times of export restrictions, it is clear how dependent the world is on China and Russia. Without the crucial raw materials, production comes to a halt. We take a look at three companies and assess whether they are well-positioned in the raw materials sector for the upcoming year.
Read